AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 200435
Drug: Fosazepam 100
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosazepam 100 mg
Trial: 31512716
Drug: Sevoflurane-based anaesthetic
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane-based anaesthetic regimen (1-3% sevoflurane inhalation during anaesthesia maintenance)
Trial: 31512716
Drug: Propofol-based anaesthetic
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-based anaesthetic regimen (6-10 mg/kg/h propofol infusion during anaesthesia maintenance)
Trial: 24498845
Drug: Chelladaghi herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chelladaghi herbal extract (suppository) administered every 12 hours from 24 hours before to 24 hours after surgery.
Trial: 24498845
Drug: Chelladaghi herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chelladaghi herbal extract (oral) administered from 24 hours before to 24 hours after surgery.
Trial: 24498845
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered from 24 hours before to 24 hours after surgery.
Trial: 20887365
Drug: Rufinamide (3,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rufinamide (3,200 mg/day)
Trial: 15329830
Drug: Doxylamine-pyridoxine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxylamine-pyridoxine combination (5-12 tablets/day)
Trial: 15329830
Drug: Doxylamine-pyridoxine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxylamine-pyridoxine combination (1-4 tablets/day)
Trial: 11432893
Drug: Topotecan 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 0.5 mg/m²/d and carboplatin AUC of 4
Trial: 11432893
Drug: Topotecan 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 0.5 mg/m²/d and carboplatin AUC of 5
Trial: 11432893
Drug: Topotecan 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 0.75 mg/m²/d and carboplatin AUC of 5
Trial: 11432893
Drug: Topotecan 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 1.0 mg/m²/d and carboplatin AUC of 5
Trial: 11432893
Drug: Topotecan 1
RxNorm normalized name: topotecan 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 1 mg/m²/d and carboplatin AUC of 5
Trial: 8345497
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (atenolol, nifedipine, captopril)
Trial: 27091810
Drug: mFOLFOX6 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 plus aflibercept (4 mg/kg)
Trial: 22108774
Drug: Fluconazole 200
RxNorm normalized name: fluconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 200 mg once daily (first dose 400 mg) for 5 days
Trial: 22108774
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg twice daily (first dose 200 mg) for 5 days
Trial: 15516364
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (15 g down to 2.5 g daily)
Trial: 11206017
Drug: Open-label dalteparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label dalteparin, administered before percutaneous coronary intervention within 7 days
Trial: 8789431
Drug: Isotretinoin alone
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin alone (Roaccutan, Roche) 1 mg/kgr orally daily for 3 months or until remission achieved
Trial: 8789431
Drug: Interferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐2a (Roferon‐A, Roche) 3 million units subcutaneously three times for 8 weeks plus isotretinoin 1 mg/Kg orally for 3 months or until remission achieved
Trial: 26519549
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) vaccine
Trial: 26519549
Drug: Standard subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard subcutaneous (SC) vaccine
Trial: 12633915
Drug: Cocaine 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine 12.5 mg
Trial: 12633915
Drug: Cocaine 25
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine 25 mg
Trial: 12633915
Drug: Cocaine 50
RxNorm normalized name: cocaine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine 50 mg
Trial: 11113721
Drug: Crataegus Special
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crataegus Special Extract WS 1442 (450 mg, standardized to 84.3 mg of oligomeric procyanidines)
Trial: 9361129
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of Polypodium leucotomos (PL)
Trial: 9361129
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Polypodium leucotomos (PL)
Trial: 9361129
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (untreated or treated with oral psoralens)
Trial: 26407909
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg kg‐1 per day topical CHE
Trial: 26407909
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg kg‐1 per day topical CHE
Trial: 20103694
Drug: Milnacipran 300
RxNorm normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milnacipran 300 mg bid
Trial: 20103694
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg single dose)
Trial: 10430348
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT) at 2.0 atm with inhalation of 100% oxygen for 60 min, at 3 hours and 24 hours after hepatectomy
Trial: 7539237
Drug: Liver resection
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liver resection combined with pre‐ and post‐operative locoregional chemotherapy‐immunotherapy (Group B)
Trial: 31330044
Drug: Soil heterogeneity
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Soil heterogeneity (three soil types assigned to patches)
Trial: 29738389
Drug: Endolymphatic sac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endolymphatic sac decompression with steroid injection (n=18)
Trial: 29738389
Drug: Endolymphatic sac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endolymphatic sac decompression without steroid injection (n=17)
Trial: 17592006
Drug: Variability in
RxNorm normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variability in formulations used to compound caffeine
Trial: 15341667
Drug: Glutamine-enriched enteral
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine-enriched enteral nutrition (0.3 g/kg/day)
Trial: 12297845
Drug: Interferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐2b (3 million units 3 times a week) plus ribavirin (1,000 mg/day) for 48 weeks
Trial: 9503102
Drug: Carvedilol combined
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol combined with a diuretic
Trial: 8301791
Drug: 22‐mg nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22‐mg nicotine patch
Trial: 3382069
Drug: Immediate whole‐bowel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate whole‐bowel irrigation with a polyethylene glycol solution
Trial: 3382069
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g oral activated charcoal followed by whole‐bowel irrigation
Trial: 3382069
Drug: Oral activated
RxNorm normalized name: activated charcoal Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral activated charcoal alone
Trial: 25948437
Drug: Grape seed
RxNorm normalized name: grape seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape seed extract 2% cream
Trial: 23101282
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of propafenone and bisoprolol (group B, n = 82)
Trial: 20495925
Drug: Liquid taste
RxNorm normalized name: 60 Second Taste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid taste solutions with different concentrations of each tastant (sweet 0.03, 0.1, 0.4, 2 g/mL sucrose solution; sour 0.01, 0.05, 0.1, 0.15 mL citric acid; salty 0.025, 0.075, 0.15, 0.36 mL sodium chloride solution; bitter 0.0002, 0.0005, 0.001, 0.01 mL quinine hydrochloride)
Trial: 20495925
Drug: Liquid taste
RxNorm normalized name: 60 Second Taste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid taste solutions
Trial: 18946064
Drug: Alemtuzumab (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alemtuzumab (12 mg or 24 mg per day) for 36 months
Trial: 8986493
Drug: Diazepam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.5 mg/kg loading dose followed by 1 mg/kg infusion over 24 h)
Trial: 31717728
Drug: Four 30‐min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four 30‐min daily outdoor unstructured play periods for 8 weeks
Trial: 26338726
Drug: Metronidazole group
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole group (lansoprazole 30 mg, amoxicillin 1 g, bismuth potassium citrate 220 mg, metronidazole 400 mg)
Trial: 26338726
Drug: Clarithromycin group
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin group (lansoprazole 30 mg, amoxicillin 1 g, bismuth potassium citrate 220 mg, clarithromycin 500 mg)
Trial: 21722580
Drug: General activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General activities of daily living
Trial: 2172535
Drug: Perilesional injections
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perilesional injections of alpha-interferon (twice-weekly)
Trial: 24168257
Drug: Narlaprevir monotherapy
RxNorm normalized name: Paritaprevir
DrugBank: Paritaprevir (DB09297)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Narlaprevir monotherapy for one week
Trial: 24168257
Drug: Narlaprevir/pegylated interferon-alpha-2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narlaprevir/pegylated interferon-alpha-2b combination therapy for two weeks
Trial: 24168257
Drug: Narlaprevir dosing
RxNorm normalized name: Paritaprevir
DrugBank: Paritaprevir (DB09297)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Narlaprevir dosing
Trial: 24168257
Drug: Narlaprevir treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narlaprevir treatment
Trial: 6210867
Drug: Post-treatment follow-up
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment follow-up
Trial: 15005645
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg Phase 2 twice daily with meals
Trial: 8872666
Drug: NG-mononmethyl-L-arginine infusion
RxNorm normalized name: L-Ng-monomethyl Arginine
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG-mononmethyl-L-arginine infusion
Trial: 2574084
Drug: Somatostatin (SMS)
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (SMS) infusion (4 micrograms/min)
Trial: 2574084
Drug: Somatostatin (SMS)
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (SMS) infusion
Trial: 1097203
Drug: Oral ephedrine
RxNorm normalized name: ephedrine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ephedrine (25 mg)
Trial: 30245189
Drug: Ruxolitinib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (20 mg twice daily)
Trial: 31730370
Drug: Augmented treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented treatment (titrated risperidone)
Trial: 31730370
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment (placebo)
Trial: 28805135
Drug: Dabrafenib 150
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib 150 mg twice daily plus trametinib 2 mg once daily (initially continuous dosing)
Trial: 28805135
Drug: Intermittent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent dosing schedule (five‐week‐on and three‐week‐off)
Trial: 28805135
Drug: Intermittent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent dosing schedule
Trial: 23443947
Drug: Control (4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (4% lidocaine cream and Tc-99m)
Trial: 16972829
Drug: 0.5 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg.kg‐1 oral midazolam (M)
Trial: 9247476
Drug: 9 MU
RxNorm normalized name: CHEMSTRIP 9 MULTIPLE TEST STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 MU IFN in patients with intermediate virus load (10(4)‐10(5) copies/mL)
Trial: 9247476
Drug: 6 MU
RxNorm normalized name: Pancrelipase 16 mu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 MU IFN in patients with intermediate virus load (10(4)‐10(5) copies/mL)
Trial: 3651531
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose infusion
Trial: 3651531
Drug: Lactate and
RxNorm normalized name: Ammonium lactate and salicylic acid only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate and Isoproterenol infusions
Trial: 31038440
Drug: Weekly ballet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly ballet classes
Trial: 26468478
Drug: Sour tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sour tea pill (500 mg)
Trial: 21242557
Drug: EHR-based clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EHR-based clinical decision support for patients on low-dose aspirin
Trial: 21242557
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care for patients on low-dose aspirin
Trial: 16922930
Drug: Intranasal immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal immunization with E-GTF (n = 7)
Trial: 12893996
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of relaxation and imagery delivered on two evenings
Trial: 9375877
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose amitriptyline (up to 30 mg nightly)
Trial: 8269183
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (12 g/d for 3 weeks)
Trial: 8269183
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (12 g/d for 3 weeks)
Trial: 2994988
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 to 20 mg twice‐daily) and Hydrochlorothiazide (50 to 100 mg/day)
Trial: 2994988
Drug: Triple-drug therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-drug therapy (Hydrochlorothiazide (50 to 100 mg/day), Timolol (10 to 30 mg twice‐daily), Hydralazine (50 to 150 mg twice‐daily)
Trial: 27603903
Drug: Diazoxide (DZX)
DrugBank: Diazoxide (DB01119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazoxide (DZX) 4 mg/kg/d for 6 months
Trial: 20171357
Drug: IAN block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAN block administered with a peripheral nerve stimulator
Trial: 18598837
Drug: Ciprofloxacin and
RxNorm normalized name: ciprofloxacin and ornidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin and hydrocortisone (CHC) 3 drops twice daily for 7 days
Trial: 18598837
Drug: NPH +
RxNorm normalized name: INSULIN,NPH,BEEF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH + AMX (neomycin/polymyxin b/hydrocortisone with systemic amoxicillin)
Trial: 8530574
Drug: Nafarelin (NAF;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin (NAF; 400 micrograms, intranasal spray, twice daily)
Trial: 8530574
Drug: Norethindrone (NOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethindrone (NOR 1/35; 0.035 mg, daily, for 3 of 4 weeks)
Trial: 8530574
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Nafarelin and Norethindrone
Trial: 7037351
Drug: Optisulin ‐depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optisulin ‐depot CS (25% dissolved porcine Des‐Phe‐insulin/insulin and 75% crystalline porcine insulin)
Trial: 7037351
Drug: Depot Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Depot Insulin Hoechst CS
Trial: 7037351
Drug: Insulin Leo
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin Leo Mixtard
Trial: 23049590
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid (ICS) treatment for 6 weeks
Trial: 18182872
Drug: Hand acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand acupuncture therapy using New Seoam Press Pellets number 1 for 4 weeks
Trial: 16089103
Drug: Chemo-radiotherapy (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-radiotherapy (cisplatin + etoposide + early concurrent thoracic radiotherapy)
Trial: 16089103
Drug: Chemotherapy (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cisplatin + etoposide)
Trial: 8606523
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg talinolol
Trial: 8606523
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg talinolol
Trial: 8606523
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg talinolol
Trial: 2291875
Drug: Medifoxamine 100
RxNorm normalized name: Medifoxamine
DrugBank: Medifoxamine (DB13219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medifoxamine 100 mg by i.v. infusion over 15 min
Trial: 2291875
Drug: Medifoxamine 500
RxNorm normalized name: Medifoxamine
DrugBank: Medifoxamine (DB13219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medifoxamine 500 mg by mouth fasting
Trial: 2291875
Drug: Oral Medifoxamine
RxNorm normalized name: Medifoxamine
DrugBank: Medifoxamine (DB13219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Medifoxamine
Trial: 7396472
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of probenecid administered concomitantly with 2 g of cefoxitin intravenously
Trial: 7396472
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of probenecid administered 1 hour prior to 2 g of cefoxitin intravenously
Trial: 7396472
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of probenecid administered with 2 g of cefoxitin intramuscularly
Trial: 7396472
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of probenecid administered before 2 g of cefoxitin intravenously
Trial: 23314231
Drug: Subthreshold argon
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subthreshold argon laser therapy
Trial: 19563191
Drug: Injection at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection at acupoint combined with warming needle therapy
Trial: 17984151
Drug: Coaching intervention
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coaching intervention (10 weekly sessions, 15-30 minutes each over three months)
Trial: 8260371
Drug: Recombinant interleukin
RxNorm normalized name: Recombinant interleukin 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interleukin 2 (rIL-2) 120 h continuous infusion at 18 x 10(6) iu m‐2 day followed by three injections of 5FU 600 mg m‐2 at weekly intervals
Trial: 8260371
Drug: Weekly 5FU
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly 5FU (after initial treatment with rIL-2)
Trial: 3978007
Drug: Fentanyl continuous
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl continuous i.v. infusion at 1.5 microgram kg‐1 min‐1
Trial: 3978007
Drug: Fentanyl continuous
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl continuous i.v. infusion at 0.5 microgram kg‐1 min‐1